Literature DB >> 8310708

Metabolism and enantioselective pharmacokinetics of Casodex in man.

D McKillop1, G W Boyle, I D Cockshott, D C Jones, P J Phillips, R A Yates.   

Abstract

1. Five healthy male volunteers received a single oral dose (50 mg; 42 microCi) of 14C-Casodex, a racemic compound, which has its antiandrogen activity predominantly in R-Casodex, the (-)-enantiomer, with little activity in S-Casodex, the (+)-enantiomer. 2. Plasma concentrations of R-Casodex increased slowly in all subjects to reach a peak of 559-970 ng/ml between 15 and 48 h after dosing and, thereafter, declined monoexponentially with a mean half-life of 4.2 days. Plasma concentrations of S-Casodex rose rapidly to reach a peak of 32-66 ng/ml within the first 2-5 h, and then declined monoexponentially with a mean half-life of 19 h. Plasma concentrations of the racemate were in very good agreement with the sum of the enantiomer concentrations throughout the study and were very similar to concentrations of total radioactivity over the first 4 days. 3. About 80% of the radioactive dose was recovered in urine (35.8 +/- 1.7%; mean +/- SEM) and faeces (42.6 +/- 2.9%) during a total collection over 9 days; this incomplete recovery was consistent with the slow elimination of R-Casodex. 4. T.l.c. of urine extracts indicated extensive metabolism of Casodex to two polar metabolites identified as the glucuronide conjugates of Casodex and hydroxy-Casodex; almost no parent compound was observed. Virtually all of the Casodex glucuronide excreted in urine during the first 2 days was derived from S-Casodex, consistent with the relatively low plasma concentrations and rapid elimination of this enantiomer. 5. T.l.c. of faecal extracts showed the presence of both Casodex and hydroxy-Casodex; these may have been eliminated in bile as the glucuronide conjugates, with subsequent hydrolysis in the intestinal tract.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8310708     DOI: 10.3109/00498259309059435

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  9 in total

Review 1.  Chemistry and structural biology of androgen receptor.

Authors:  Wenqing Gao; Casey E Bohl; James T Dalton
Journal:  Chem Rev       Date:  2005-09       Impact factor: 60.622

Review 2.  Bicalutamide in advanced prostate cancer. A review.

Authors:  K L Goa; C M Spencer
Journal:  Drugs Aging       Date:  1998-05       Impact factor: 3.923

3.  Characterization of the in vitro metabolism of selective androgen receptor modulator using human, rat, and dog liver enzyme preparations.

Authors:  Wenqing Gao; Zengru Wu; Casey E Bohl; Jun Yang; Duane D Miller; James T Dalton
Journal:  Drug Metab Dispos       Date:  2005-11-04       Impact factor: 3.922

Review 4.  Bicalutamide: in early-stage prostate cancer.

Authors:  Christopher I Carswell; David P Figgitt
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 5.  Bicalutamide: clinical pharmacokinetics and metabolism.

Authors:  Ian D Cockshott
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

6.  Pharmacokinetics and metabolism of a selective androgen receptor modulator in rats: implication of molecular properties and intensive metabolic profile to investigate ideal pharmacokinetic characteristics of a propanamide in preclinical study.

Authors:  Di Wu; Zengru Wu; Jun Yang; Vipin A Nair; Duane D Miller; James T Dalton
Journal:  Drug Metab Dispos       Date:  2005-12-28       Impact factor: 3.922

Review 7.  Pharmacokinetics and pharmacodynamics of nonsteroidal androgen receptor ligands.

Authors:  Wenqing Gao; Juhyun Kim; James T Dalton
Journal:  Pharm Res       Date:  2006-08       Impact factor: 4.200

8.  Enantiomer selective glucuronidation of the non-steroidal pure anti-androgen bicalutamide by human liver and kidney: role of the human UDP-glucuronosyltransferase (UGT)1A9 enzyme.

Authors:  Laurent Grosse; Anne-Sophie Campeau; Sarah Caron; Frédéric-Alexandre Morin; Kim Meunier; Jocelyn Trottier; Patrick Caron; Mélanie Verreault; Olivier Barbier
Journal:  Basic Clin Pharmacol Toxicol       Date:  2013-05-20       Impact factor: 4.080

9.  Metabolic Hydrolysis of Aromatic Amides in Selected Rat, Minipig, and Human In Vitro Systems.

Authors:  Peter R Bradshaw; Ian D Wilson; Rachel Upcott Gill; Philip J Butler; Clive Dilworth; Toby J Athersuch
Journal:  Sci Rep       Date:  2018-02-05       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.